SpringWorks’ Ogsiveo Is First-Ever US FDA-Approved Drug For Desmoid Tumors
Nirogacestat Also In Anti-BCMA Combo, Ovarian Cancer Studies
Executive Summary
SpringWorks’ gamma secretase inhibitor will be available soon for adults at any stage of treatment for desmoid tumors with a list price of $29,000 for a 30-day supply.